Research Topics
| Fredrick B HagemeisterSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapyFredrick B Hagemeister
Department of Lymphoma/Myeloma, Univeristy of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Adv Hematol Oncol 1:120-5. 2003..Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care...- Hodgkin's lymphoma in younger patients: lessons learned on the road to successFredrick B Hagemeister
Department of Hematology, The University of Texas M D Anderson Cancer Center Houston, Texas 77030, USA
Oncology (Williston Park) 21:434-40; discussion 441-2, 445-6. 2007.... - Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimenApostolia-Maria Tsimberidou
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 104:345-53. 2005..The overall safety profile for FND was good. However, patients should be monitored for opportunistic infections, and prophylactic antibiotics are recommended, particularly against PCP... - An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin diseaseGregory M Chronowski
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 95:2534-8. 2002..The relative importance of prognostic factors in patients with early-stage Hodgkin disease remains controversial. The purpose of this study was to evaluate prognostic factors among patients who received chemotherapy before radiotherapy... 
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Br J Haematol 150:200-8. 2010..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...- Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphomaAmar Safdar
Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Infect Dis 194:1394-7. 2006..For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine... - European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin diseaseRichard B Wilder
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 94:1731-8. 2002.... 
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alphaPeter McLaughlin
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, USA
Blood 105:4573-5. 2005..MDS with features classically associated with DNA-damaging agents can occur following therapy with FND, with or without rituximab, and IFN-alpha...- Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphomaNam H Dang
The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
J Clin Oncol 22:4095-102. 2004..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL... - Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the dataFredrick B Hagemeister
Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
Curr Oncol Rep 12:395-401. 2010.... - Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang
MD Anderson Cancer Center, Houston, TX 77030, USA
Oncol Rep 10:1513-8. 2003..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications... - Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experienceApostolia Maria Tsimberidou
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 107:1294-302. 2006..In this study, the authors assessed the incidence, presenting characteristics, and outcomes of patients with CLL/SLL who developed Hodgkin lymphoma (HL)... - Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literatureAndres O Soriano
Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Am J Hematol 82:725-8. 2007..A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease... - Lymphoma of the colonJorge Romaguera
University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
Curr Opin Gastroenterol 21:80-4. 2005..Emphasis is on new entities such as mantle cell (MCL) and marginal zone (MZL) lymphomas. Presenting symptoms and signs are described where applicable and treatment and prognosis are covered briefly... - Thalidomide for patients with recurrent lymphomaBarbara Pro
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 100:1186-9. 2004..However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non-Hodgkin lymphoma and in patients with Hodgkin disease... - Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphomaJoseph D Khoury
Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Am J Surg Pathol 28:489-95. 2004..Although the best terminology for these bone marrow lymphomas is uncertain, the aggressive clinical behavior of these neoplasms supports the need for intensive therapy... - Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescueFredrick B Hagemeister
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, Texas 77030, USA
Cancer Chemother Pharmacol 49:S13-20. 2002..Finally, we have recently studied paclitaxel in combination with topotecan for relapsed and refractory aggressive lymphomas. These and newer combinations should be further developed to treat patients in relapse of aggressive lymphomas... - Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaApostolia M Tsimberidou
Department of Lymphoma and Myeloma, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
Blood 100:4351-7. 2002..In conclusion, both regimens were associated with high rates of response and survival. ATT was associated with substantially longer FFS, but it was more toxic than FND... - Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphomaNam H Dang
Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
Br J Haematol 136:439-47. 2007..Further studies of denileukin diftitox in combination with other agents are warranted in previously untreated and relapsed/refractory T-NHL... - Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphomaBarbara Pro
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Leuk Lymphoma 47:1818-21. 2006..The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL... - Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapyGregory M Chronowski
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 55:36-43. 2003.... - Combination treatment approaches and novel therapies for lymphomaJohn P Leonard
Clin Adv Hematol Oncol 5:4-20; quiz 1 p following 20. 2007 - Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
Cancer 106:1569-80. 2006..CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients... - Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphomaBarbara Pro
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Leuk Lymphoma 47:481-5. 2006..In these previously treated patients with NHL, a single dose of pegfilgrastim was effective in promoting neutrophil count recovery after paclitaxel and topotecan, and allowed patients to receive the next planned dose on time... - Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphomaYasuhiro Oki
Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Cancer 104:781-7. 2005..The favorable safety profile and the ease of its administration in outpatient settings warrant investigating it in combination with other active drugs for the treatment of recurrent and refractory NHL... - NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21Sara Frias
Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, Livermore, California 94550, USA
Cancer Res 63:44-51. 2003.... - Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour
Department of Haematology, The Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
J Clin Oncol 21:2115-22. 2003..This apparent improvement is being further explored in an ongoing randomized trial... - Second malignancies after chemotherapy and radiotherapy for Hodgkin diseaseGregory M Chronowski
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Am J Clin Oncol 27:73-80. 2004..08). In an effort to reduce the risk of second malignancies, we have stopped using the alkylating agents nitrogen mustard and procarbazine and elective paraaortic and splenic radiotherapy after chemotherapy... - Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer CenterQi Liu
Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:1582-9. 2006..The apparent plateau in the FFS curve, starting approximately 8 to 10 years from the beginning of treatment, raises the issue of the potential curability of these patients...